Patents by Inventor Hans Kretzschmar

Hans Kretzschmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10435373
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: October 8, 2019
    Assignees: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Publication number: 20180346426
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V.
    Inventors: Armin GIESE, Uwe BERTSCH, Hans KRETZSCHMAR, Matthias HABECK, Thomas HIRSCHBERGER, Paul TAVAN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Petra FRICK née WEBER, Markus GEISSEN, Martin H. GROSCHUP, Jens WAGNER
  • Patent number: 10071966
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 11, 2018
    Assignees: LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Publication number: 20160185730
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Applicants: Ludwig-Maximilians-Universität München, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Publication number: 20110293520
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R1)(R2)—, —C(R3)?, —N(R4)—, —N?, —N+(R5)?, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).
    Type: Application
    Filed: June 9, 2009
    Publication date: December 1, 2011
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Mathias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Publication number: 20100029773
    Abstract: The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.
    Type: Application
    Filed: May 24, 2005
    Publication date: February 4, 2010
    Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT FUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Uwe Bertsch, Armin Giese, Hans Kretzschmar, Paul Tavan, Thomas Hirschberger, Jan Bieschke, Petra Weber, Konstanze F. Winklhofer, Jörg Tatzelt, Ulrich F. Hartl, Gerda Mitterregger-Kretzschmar, Tobias Johannes Högen
  • Publication number: 20080070233
    Abstract: A method for the determination and individual characterization of particles by means of at least two different detectable probes in a sample is proposed, wherein the particles, especially molecules or molecular aggregates, have at least one binding site, preferably a multitude of binding sites, for at least one of said at least two different detectable probes; said at least two different detectable probes are present in the sample; a measure of the number of bound probes and the mutual ratio of bound probes are established by determining particles; said determining being effected on the basis of single particles.
    Type: Application
    Filed: May 3, 2007
    Publication date: March 20, 2008
    Inventors: Jan Bieschke, Armln Goese, Manfred Eigen, Hans Kretzschmar
  • Publication number: 20050147989
    Abstract: A method for the identification of substances for influencing aggregations comprising the following steps: a) combining at least one aggregate having a first detectable function and at least one monomer having a second detectable function, wherein said at least one monomer has an affinity for said at least one aggregate, in the presence of a potentially aggregation-influencing substance; b) determining a degree of labeling of the aggregates, the degree of labeling being a measure of the number and proportion of the detectable functions bound.
    Type: Application
    Filed: October 1, 2004
    Publication date: July 7, 2005
    Inventors: Uwe Bertsch, Armin Giese, Hans Kretzschmar, Jan Bieschke